The Other Agency: CMS Shocks Wall Street-and Amgen Takes a Hit

Biotech investors are used to worrying about what FDA will or won't do to a blockbuster drug, especially in the current climate of drug safety hysteria. But Wall Street didn't expect the federal Medicare agency to get into the act.